Corbion Welcomes Per Falholt to Enhance Leadership Team
Corbion Nominates Per Falholt for Supervisory Board
Corbion’s Supervisory Board is excited to announce the nomination of Per Falholt for a four-year term to join the Supervisory Board, which will commence following the Annual General Meeting of Shareholders. This significant appointment is set for May 2026.
Mr. Falholt’s Extensive Background
Per Falholt, who hails from Denmark, comes with a wealth of experience in both research and development as well as leadership within the biotechnology and life sciences fields. He currently serves as an Operating Partner at Forbion, a venture capital firm based in the Netherlands. Additionally, he is a co-founder and the Chief Scientific Officer of 21st.BIO. His extensive portfolio also includes prestigious roles such as Chairman of the Board for DHI Foundation and Board Member for CO-RO A/S and Danfoss A/S. Prior to these roles, he was the Executive Vice President at Novozymes, where he directed global R&D initiatives and innovation strategies. Mr. Falholt earned a Master’s Degree in Chemical Engineering from the Technical University of Denmark.
Emphasizing Leadership in R&D
Ilona Haaijer, Chair of the Supervisory Board, expressed enthusiasm regarding the nomination. She stated, 'We are delighted to welcome Per Falholt to our Supervisory Board. His extensive knowledge in R&D and innovation, combined with strong leadership skills and sound academic background, will be essential as we progress with our strategic initiatives. We have every confidence that Per's insights will significantly contribute to our goal of driving value creation at Corbion.'
Future Contributions and Strategic Goals
Starting from October 1, 2025, Mr. Falholt will begin his role as an advisor to the Board, preparing for his official appointment. His nomination comes as Mr. Steen Riisgaard concludes his term and will not seek reappointment after the AGM in 2026.
Pending the approval from the AGM, Mr. Falholt’s official appointment will be realized at the end of the General Meeting in May 2026. In the lead-up to this event, additional details, including the agenda for the AGM, will be shared in April 2026.
Frequently Asked Questions
Who is Per Falholt?
Per Falholt is a Danish biotechnology expert with over 40 years of experience in R&D, currently serving as an Operating Partner at Forbion.
What roles does Mr. Falholt hold?
He is the co-founder and Chief Scientific Officer at 21st.BIO and has held leadership positions at companies like Novozymes.
When will Mr. Falholt join the Supervisory Board?
He is set to join the Supervisory Board officially in May 2026 following the AGM.
What is Corbion’s strategic initiative?
Corbion aims to enhance value creation through innovation and development in the biotechnology sector.
Why is this appointment significant?
Mr. Falholt’s extensive background in R&D and leadership aligns with Corbion’s vision for innovation and strategic advancement.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.